Our quarterly overview of the healthcare and life sciences sector delves into R&D partnerships, M&A, venture activity, and highlights notable deals. Check out our research on our blog. hubs.ly/Q02HK_020

Our H1 2024 review of the gene therapy sector explores R&D partnerships, M&A activity, venture investments, and industry trends. Check out our research on our blog. hubs.ly/Q02HL8bf0

From 2019 to 2024, total M&A upfront cash and equity have been in Phase III deals with $118.2B, Phase II with $54.4B, Phase I with $27.6B, preclinical with $9.2B, and platform deals with $1.7B. Want to see more charts like this? Schedule your demo hubs.ly/Q02H_l4X0

The total M&A upfront cash and equity for immunotherapy peaked in 2018 at $20.8B, in 2019 with $8.2B. Since then, annual totals have varied, with $3.0B in 2020, $0.9B in 2021, $0.8B in 2022, and $1.4B in 2023. See more charts like this. Schedule your demo hubs.ly/Q02H_YD30

In 2024, large-cap biopharma companies acquired smaller biopharma firms primarily in the approved and Phase II stages, with significant activity also seen in Phase I, preclinical, and platform stages. Want to see more charts like this? Schedule your demo hubs.ly/Q02H_YTC0

In 2023-2024 YTD, the top M&A buyers by upfront cash and equity include Pfizer Inc. at $43.4 billion, BMS at $22.9 billion, @AbbVie at $18.9 billion, and J&J/Janssen at $17.6 billion. Want to see more charts like this? Schedule your demo hubs.ly/Q02JjqLd0

The median M&A upfront cash and equity for biopharma transactions on the buy-side has shown significant variation from 2018 to 2024. The most notable spike occurred in the second half of 2021, reaching $412 million. Schedule your demo hubs.ly/Q02Jjyyp0

From 2019 to 2024, the median M&A 1-day share premium percentage by therapeutic area shows that deals in inflammation had the highest premium at 116%, followed by musculoskeletal at 82%... Want to see more charts like this? Schedule your demo hubs.ly/Q02JF2cH0

Our quarterly review of biopharma therapeutics and platforms dives deep into M&A deals.Vertex Pharmaceuticals acquired Alpine Immune Sciences in April 2024, enhancing its immunotherapy portfolio. Read the rest of our research on our blog. hubs.ly/Q02JQc4J0

Join DealForma and Johnson & Johnson for an insightful webinar tomorrow, 8/8 at 1pm PST, where DealForma's CEO, Chris Dokomajilar, will be discussing Biopharma deal and funding activity through Q2 and providing a 2024 outlook. Register for the webinar hubs.ly/Q02KssKc0

Our quarterly overview of R&D partnerships in biopharma therapeutics and platforms provides a detailed summary of significant deals completed during Q2 2024. Check out our full report hubs.ly/Q02KGnrh0

Nature’s report explores the current state of biotech financing, detailing robust M&A activity and significant private funding rounds, contrasted with difficult public markets and selective venture capital investments, using data from DealForma. Read more hubs.ly/Q02KQKb60

The WSJ article, using data from DealForma, discusses how major pharmaceutical companies have scaled down their acquisition strategies in 2024, focusing on smaller targets priced at $5 billion or less. Check out WSJ’s article. hubs.ly/Q02L2xF60

Stifel’s report, utilizing DealForma’s data, outlines the recent market turbulence, focusing on the sharp declines in tech and biotech stocks due to changes in Japanese interest rates and the resulting impact on investors. Explore Stifel’s research. hubs.ly/Q02L2GYx0

DealForma put together this comprehensive PDF report on Biopharma Q2 Deals and Funding overview. This report includes: * Biopharma Licensing Activity * Top Dealmakers * Top Therapy Areas and Modalities * ... and much more! Download this FREE report! hubs.ly/Q02Lsjvv0

DealForma put together this comprehensive PDF report on Biopharma Q2 Deals and Funding overview. This report includes: * Biopharma Licensing Activity * Top Dealmakers * Top Therapy Areas and Modalities * and more... Download this FREE report! hubs.ly/Q02LzZBS0

Watch the recording of Johnson & Johnson's webinar with DealForma's CEO, Chris Dokomajilar, providing insight into biopharma dealmaking and funding with recent data through Q2 2024. Watch here and send your questions to us to be answered by Chris. hubs.ly/Q02LBrsf0

Our quarterly review of the medtech sector provides an in-depth analysis of M&A and venture investments, showcasing the sector’s biggest deals. Read our research on our blog. hubs.ly/Q02Md2-B0

Our H1 2024 analysis of the cardiovascular sector explores notable M&As, R&D partnerships, and ventures. Check out our full research! hubs.ly/Q02N4yQs0

Our Q2 2024 cancer review delves into R&D and licensing partnership activity, investments, IPOs and M&A. Check out our research. hubs.ly/Q02N-w1C0